{"id":{"repo_id":"clemson","oai_identifier":"oai:open.clemson.edu:all_theses-5356"},"canonical_url":"https://search.ndltd.org/etd/clemson/oai:open.clemson.edu:all_theses-5356","repository":{"repo_id":"clemson","name":"Clemson University","base_url":"https://open.clemson.edu/do/oai/"},"display":{"title":"PFOS Alters Metabolism in the Liver and Skeletal Muscle of CYP2B-Null and Humanized CYP2B6-Transgenic Mice","abstract":"Perfluorooctanesulfonate (PFOS) is a persistent environmental pollutant previously used in industrial products such as fire-fighting foams, furniture, and stain-resistant coatings. PFOS is associated with adverse health outcomes, including hepatosteatosis and diabetes. Previously, humanized CYP2B6-transgenic (hCYP2B6-Tg) mice accumulated more PFOS than Cyp2b-null mice and experienced greater mortality; however, the Cyp2b-null mice experienced greater steatosis. Cyp2b-null and hCYP2B6-Tg mice were treated with 0, 1, or 10 mg/kg/day PFOS for 21 days. To determine how PFOS affected the metabolism of polyunsaturated fatty acids (PUFAs) oxylipin concentrations were measured via LC-MS/MS. Additionally, gene expression changes were measured using RNA sequencing. PFOS treatment increased the expression of soluble epoxide hydrolase enzymes which correlated with increased concentrations of diol- and decreased epoxide-containing oxylipins. PFOS-mediated liver toxicity was also associated with perturbed arachidonic acid metabolism. Several hepatic Oatps (Oatp1a4-6) were increased in the hCYP2B6-Tg females compared to the Cyp2b-null females, which may have increased hepatic PFOS uptake and retention. In addition to altered hepatic lipid metabolism, PFOS-treated Cyp2b-null and hCYP2B6-Tg mice experienced muscle wasting with PFOS. Our lab has previously demonstrated reduced mitochondrial capacity in PFOS-treated C2C12 cells, so we wanted to determine if mitochondrial function was affected in the Cyp2b-null and hCYP2B6-Tg skeletal muscle. We performed Respirometry in Frozen Samples (RIFS) assay to measure mitochondrial complex function. PFOS decreased complex I and IV function. The purpose of this study is to elucidate PFOS’ mechanism of hepatic retention, characterize how it changes PUFA metabolism and its effect on skeletal muscle metabolism.","abstract_html":"Perfluorooctanesulfonate (PFOS) is a persistent environmental pollutant previously used in industrial products such as fire-fighting foams, furniture, and stain-resistant coatings. PFOS is associated with adverse health outcomes, including hepatosteatosis and diabetes. Previously, humanized CYP2B6-transgenic (hCYP2B6-Tg) mice accumulated more PFOS than Cyp2b-null mice and experienced greater mortality; however, the Cyp2b-null mice experienced greater steatosis. Cyp2b-null and hCYP2B6-Tg mice were treated with 0, 1, or 10 mg/kg/day PFOS for 21 days. To determine how PFOS affected the metabolism of polyunsaturated fatty acids (PUFAs) oxylipin concentrations were measured via LC-MS/MS. Additionally, gene expression changes were measured using RNA sequencing. PFOS treatment increased the expression of soluble epoxide hydrolase enzymes which correlated with increased concentrations of diol- and decreased epoxide-containing oxylipins. PFOS-mediated liver toxicity was also associated with perturbed arachidonic acid metabolism. Several hepatic Oatps (Oatp1a4-6) were increased in the hCYP2B6-Tg females compared to the Cyp2b-null females, which may have increased hepatic PFOS uptake and retention. In addition to altered hepatic lipid metabolism, PFOS-treated Cyp2b-null and hCYP2B6-Tg mice experienced muscle wasting with PFOS. Our lab has previously demonstrated reduced mitochondrial capacity in PFOS-treated C2C12 cells, so we wanted to determine if mitochondrial function was affected in the Cyp2b-null and hCYP2B6-Tg skeletal muscle. We performed Respirometry in Frozen Samples (RIFS) assay to measure mitochondrial complex function. PFOS decreased complex I and IV function. The purpose of this study is to elucidate PFOS’ mechanism of hepatic retention, characterize how it changes PUFA metabolism and its effect on skeletal muscle metabolism.","abstract_has_math":false,"creators":["Williams, Lanie"],"institution":null,"degree_name":"Master of Science (MS)","degree_level":"Thesis","degree_discipline":"Biological Sciences","degree_department":null,"school":null,"contributors":["William Baldwin","Lisa Bain","Subham Dasgupta"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T07:32:50Z","subjects":["Perfluorooctanesulfonate","fatty liver disease","steatosis","oxylipin","skeletal muscle","mitochondrial metabolism","Biology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://open.clemson.edu/all_theses/4331","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://open.clemson.edu/all_theses/4331","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.clemson.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Aopen.clemson.edu%3Aall_theses-5356","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["William Baldwin","Lisa Bain","Subham Dasgupta"]},{"key":"dc:creator","label":"Author","values":["Williams, Lanie"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2024-05-03T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2024-08-01T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biological Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (MS)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Perfluorooctanesulfonate","fatty liver disease","steatosis","oxylipin","skeletal muscle","mitochondrial metabolism","Biology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://open.clemson.edu/all_theses/4331"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Perfluorooctanesulfonate (PFOS) is a persistent environmental pollutant previously used in industrial products such as fire-fighting foams, furniture, and stain-resistant coatings. PFOS is associated with adverse health outcomes, including hepatosteatosis and diabetes. Previously, humanized CYP2B6-transgenic (hCYP2B6-Tg) mice accumulated more PFOS than Cyp2b-null mice and experienced greater mortality; however, the Cyp2b-null mice experienced greater steatosis. Cyp2b-null and hCYP2B6-Tg mice were treated with 0, 1, or 10 mg/kg/day PFOS for 21 days. To determine how PFOS affected the metabolism of polyunsaturated fatty acids (PUFAs) oxylipin concentrations were measured via LC-MS/MS. Additionally, gene expression changes were measured using RNA sequencing. PFOS treatment increased the expression of soluble epoxide hydrolase enzymes which correlated with increased concentrations of diol- and decreased epoxide-containing oxylipins. PFOS-mediated liver toxicity was also associated with perturbed arachidonic acid metabolism. Several hepatic Oatps (Oatp1a4-6) were increased in the hCYP2B6-Tg females compared to the Cyp2b-null females, which may have increased hepatic PFOS uptake and retention. In addition to altered hepatic lipid metabolism, PFOS-treated Cyp2b-null and hCYP2B6-Tg mice experienced muscle wasting with PFOS. Our lab has previously demonstrated reduced mitochondrial capacity in PFOS-treated C2C12 cells, so we wanted to determine if mitochondrial function was affected in the Cyp2b-null and hCYP2B6-Tg skeletal muscle. We performed Respirometry in Frozen Samples (RIFS) assay to measure mitochondrial complex function. PFOS decreased complex I and IV function. The purpose of this study is to elucidate PFOS’ mechanism of hepatic retention, characterize how it changes PUFA metabolism and its effect on skeletal muscle metabolism."]},{"key":"dc:title","label":"Title","values":["PFOS Alters Metabolism in the Liver and Skeletal Muscle of CYP2B-Null and Humanized CYP2B6-Transgenic Mice"]}]}],"canonical_facts":{"dc:contributor":["William Baldwin","Lisa Bain","Subham Dasgupta"],"dc:creator":["Williams, Lanie"],"dc:date.available":["2024-05-03T07:00:00Z"],"dc:date.created":["2024-08-01T07:00:00Z"],"dc:description.abstract":["Perfluorooctanesulfonate (PFOS) is a persistent environmental pollutant previously used in industrial products such as fire-fighting foams, furniture, and stain-resistant coatings. PFOS is associated with adverse health outcomes, including hepatosteatosis and diabetes. Previously, humanized CYP2B6-transgenic (hCYP2B6-Tg) mice accumulated more PFOS than Cyp2b-null mice and experienced greater mortality; however, the Cyp2b-null mice experienced greater steatosis. Cyp2b-null and hCYP2B6-Tg mice were treated with 0, 1, or 10 mg/kg/day PFOS for 21 days. To determine how PFOS affected the metabolism of polyunsaturated fatty acids (PUFAs) oxylipin concentrations were measured via LC-MS/MS. Additionally, gene expression changes were measured using RNA sequencing. PFOS treatment increased the expression of soluble epoxide hydrolase enzymes which correlated with increased concentrations of diol- and decreased epoxide-containing oxylipins. PFOS-mediated liver toxicity was also associated with perturbed arachidonic acid metabolism. Several hepatic Oatps (Oatp1a4-6) were increased in the hCYP2B6-Tg females compared to the Cyp2b-null females, which may have increased hepatic PFOS uptake and retention. In addition to altered hepatic lipid metabolism, PFOS-treated Cyp2b-null and hCYP2B6-Tg mice experienced muscle wasting with PFOS. Our lab has previously demonstrated reduced mitochondrial capacity in PFOS-treated C2C12 cells, so we wanted to determine if mitochondrial function was affected in the Cyp2b-null and hCYP2B6-Tg skeletal muscle. We performed Respirometry in Frozen Samples (RIFS) assay to measure mitochondrial complex function. PFOS decreased complex I and IV function. The purpose of this study is to elucidate PFOS’ mechanism of hepatic retention, characterize how it changes PUFA metabolism and its effect on skeletal muscle metabolism."],"dc:identifier":["https://open.clemson.edu/all_theses/4331"],"dc:subject":["Perfluorooctanesulfonate","fatty liver disease","steatosis","oxylipin","skeletal muscle","mitochondrial metabolism","Biology"],"dc:title":["PFOS Alters Metabolism in the Liver and Skeletal Muscle of CYP2B-Null and Humanized CYP2B6-Transgenic Mice"],"thesis:degree_discipline":["Biological Sciences"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Master of Science (MS)"]},"updated_at":"2026-11-19T07:32:50Z"}